F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.62 EUR 5.88%
Market Cap: 600.1m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fluidigm Corp
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Cash from Investing Activities
$305.3m
CAGR 3-Years
353%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Investing Activities
-$6.2B
CAGR 3-Years
-17%
CAGR 5-Years
-27%
CAGR 10-Years
6%
Danaher Corp
NYSE:DHR
Cash from Investing Activities
-$7.3B
CAGR 3-Years
17%
CAGR 5-Years
-42%
CAGR 10-Years
-22%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Investing Activities
-$103.9m
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
-1%
Agilent Technologies Inc
NYSE:A
Cash from Investing Activities
-$344m
CAGR 3-Years
22%
CAGR 5-Years
8%
CAGR 10-Years
-4%
IQVIA Holdings Inc
NYSE:IQV
Cash from Investing Activities
-$1.3B
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-24%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
599.3m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
1.08 EUR
Overvaluation 33%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Cash from Investing Activities?
Cash from Investing Activities
305.3m USD

Based on the financial report for Jun 30, 2024, Fluidigm Corp's Cash from Investing Activities amounts to 305.3m USD.

What is Fluidigm Corp's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
353%

Over the last year, the Cash from Investing Activities growth was 127%. The average annual Cash from Investing Activities growth rates for Fluidigm Corp have been 353% over the past three years .

Back to Top